Microdosing Tirzepatide & Semaglutide: The Evidence

"Microdosing" a GLP-1 — staying at or below the labeled starting dose indefinitely, rather than titrating up — is a real, widely discussed practice with no dedicated clinical trial behind it. The published literature has nothing purpose-built to answer the question. What does exist is something more useful: the actual dose-response data from the pivotal trials, which shows precisely what happens at each dose along the way — including the low ones.

How much weight do you lose on a low dose of tirzepatide?

SURMOUNT-1, tirzepatide's pivotal obesity trial, randomized participants to three separate weekly maintenance doses rather than just one — a genuine dose-response design. At 72 weeks, mean weight loss was -15.0% with the 5 mg dose (the lowest labeled maintenance dose), -19.5% with 10 mg, and -20.9% with 15 mg, against -3.1% with placebo¹. That is real evidence for the microdosing question, directly on the currently approved product: the lowest approved maintenance dose still produced substantial weight loss — nearly five times placebo — but meaningfully less than the top labeled dose. Lower is not "the same, cheaper." It's measurably less, in a clean, dose-dependent line.

Does microdosing semaglutide work?

Before Wegovy's weekly 2.4 mg formulation existed, an earlier phase 2 dose-ranging trial tested five separate daily semaglutide doses from 0.05 mg up to 0.4 mg against placebo and liraglutide over 52 weeks. Mean weight loss ran from -6.0% at the lowest dose (0.05 mg) up to -13.8% at the highest (0.4 mg), against -2.3% for placebo — every single dose tested beat placebo, and the relationship between higher doses and more weight loss was consistent and statistically significant at each step². Note the caveat: this trial used an older, once-daily formulation at doses not directly comparable in milligrams to today's once-weekly Wegovy schedule, so treat it as evidence of the dose-response principle rather than a literal preview of what a "microdose" of Wegovy specifically would do. The principle it demonstrates, though, is the same one SURMOUNT-1 shows on the currently marketed drug: even a low dose beats no treatment, but a clear, real gap opens up between low and target doses.

Why the labeled starting dose isn't meant to be a destination

The starting doses on both drugs' labels — 0.25 mg for Wegovy, 2.5 mg for Zepbound — are explicitly initiation doses in the FDA-labeled titration schedule, not doses tested as a long-term maintenance strategy in the pivotal trials. Zepbound's own label states its 2.5 mg starting dose "is for treatment initiation and is not approved as a maintenance dosage." Staying there indefinitely — the literal practice of "microdosing" — is a use case the trials above did not test, which is exactly why no dedicated evidence exists to say how it performs against the maintenance doses that were studied.

Is microdosing a good way to save money?

If the appeal of microdosing is stretching a prescription to save money, the dose-response data above answers the efficacy side honestly: less drug is likely to mean less weight loss, not the same result for less money. It is also no longer purely a self-directed practice: providers now sell separately priced microdose programs as their own product line, priced well below their standard GLP-1 plans, which turns the dose-response question above into a purchasing decision rather than a private one. The better cost lever is provider selection, not self-directed underdosing — compare verified, flat-priced options on the cheapest GLP-1 ranking and price your real annual cost with the calculators before deciding a lower dose is the only way to make the budget work. If side effects, not cost, are the reason you're drawn to staying at a lower dose, that is a legitimate conversation to have with your prescriber directly — see what the trials report on side effects and ask about a slower-than-labeled titration rather than an indefinite stay at the starting dose. A stall at a maintenance dose you've already reached is a different situation with its own evidence — see the GLP-1 weight-loss plateau if that's what you're actually experiencing. The dose-response trials behind this are indexed in our research library. Not medical advice — see our medical disclaimer; any change to your dose or schedule should go through your own clinician.